These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38368200)

  • 21. GLP-1 receptor agonists for type 2 diabetes.
    De Block CE; Van Gaal LF
    Lancet; 2009 Jul; 374(9683):4-6. PubMed ID: 19515414
    [No Abstract]   [Full Text] [Related]  

  • 22. [Diabetes therapy--novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors)].
    Gallwitz B
    MMW Fortschr Med; 2010 May; 152(20):43-4. PubMed ID: 20552881
    [No Abstract]   [Full Text] [Related]  

  • 23. The possible synergistic action of sex hormones and glucagon-like peptide-1 (GLP-1) agonists on body mass decline in patients with type 2 diabetes mellitus.
    Režić T; Blaslov K; Kruljac I; Rahelić D; Vrkljan M; Renar IP
    Med Hypotheses; 2019 Oct; 131():109308. PubMed ID: 31443779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M
    Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes.
    Cheang JY; Moyle PM
    ChemMedChem; 2018 Apr; 13(7):662-671. PubMed ID: 29430842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.
    Hogan AE; Tobin AM; Ahern T; Corrigan MA; Gaoatswe G; Jackson R; O'Reilly V; Lynch L; Doherty DG; Moynagh PN; Kirby B; O'Connell J; O'Shea D
    Diabetologia; 2011 Nov; 54(11):2745-54. PubMed ID: 21744074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of glucagon-like peptide-1 receptor agonists for pediatric patients with obesity and diabetes: The providers' perspectives.
    Gourgari E; Huerta-Saenz L; Tonyushkina KN; Rosolowsky ET; Guttmann-Bauman I
    Pediatr Diabetes; 2021 Sep; 22(6):872-875. PubMed ID: 34018306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comments on "GLP-1 agonists: A review for emergency clinicians".
    Mattingly TJ; LaFleur G; Ruble JH
    Am J Emerg Med; 2024 Jun; 80():194-196. PubMed ID: 38582620
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.
    Garber AJ
    Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S279-84. PubMed ID: 21525469
    [No Abstract]   [Full Text] [Related]  

  • 32. Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
    Doggrell SA
    Expert Opin Investig Drugs; 2023 May; 32(5):355-359. PubMed ID: 37086147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs).
    Al Rifai M; Vaughan EM; Abushamat LA; Lee M; Ramsey DJ; Gupta K; Navaneethan SD; Virani SS
    Am J Cardiol; 2022 Jun; 172():7-10. PubMed ID: 35305783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delivery Device Patents on GLP-1 Receptor Agonists.
    Alhiary R; Gabriele S; Kesselheim AS; Tu SS; Feldman WB
    JAMA; 2024 Mar; 331(9):794-796. PubMed ID: 38315473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dulaglutide: first global approval.
    Sanford M
    Drugs; 2014 Nov; 74(17):2097-103. PubMed ID: 25367716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?
    Smits MM; Holst JJ
    Diabetes Metab Res Rev; 2023 Nov; 39(8):e3699. PubMed ID: 37485788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Karras SN; Rapti E; Koufakis T; Kyriazou A; Goulis DG; Kotsa K
    Curr Clin Pharmacol; 2017; 12(4):202-209. PubMed ID: 29473524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
    Iglesias P; Civantos S; Vega B; Pavón I; Guijarro G; Monereo S
    Obes Surg; 2015 Mar; 25(3):575-8. PubMed ID: 25589020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review.
    Conlon JM; O'Harte FPM; Flatt PR
    Peptides; 2022 Jan; 147():170706. PubMed ID: 34861327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cardioprotective effects of glucagon-like peptide 1 receptor agonists].
    Ametov AS; Kamynina LL; Akhmedova ZG
    Kardiologiia; 2014; 54(7):92-6. PubMed ID: 25177820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.